anonymous
Guest
anonymous
Guest
Stock price is trading at 20.4 times revenue. This company is drastically overvalued! They did 265m in 2017 revenue and posted a 165m loss!!!! How is this even possible? Their 10k statement is a cautionary tale. There press release touts revenue increase but does not mention the losses. Most investors don;t even read the 10k, but I do. Reach the entire 10k and all you Exact employees will see the company is doomed! Don no tbeleive they type! The test sucks and they know it! Also the FDA may pull approval. If you don't believe me here is statement from Exacts SEC 10k:
"The FDA granted premarket approval (“PMA”) for Cologuard in August 2014. That PMA approval places substantial restrictions on how Cologuard is marketed and sold, specifically, by prescription only. Additionally, the regulations governing our approval require controls on Cologuard, including, but not limited to, manufacturing facility registration, product listing with the FDA, complying with labeling requirements, maintenance of a satisfactory quality management system, and meeting post-market surveillance requirements. In addition, as a condition of our FDA approval, we are required to conduct a post-approval study. There can be no assurance that the results of this study will be satisfactory and will not cause the FDA to modify or withdraw our approval for Cologuard."
Exact knows the study will not be satisfactory! They are working day and night to improve the test, but can't get any results better than the FIT tests. The test does not work as most doctors will attest. If the test worked, they would perform about 2m tests per year. They only performed about 550k tests!
This test is a joke!
"The FDA granted premarket approval (“PMA”) for Cologuard in August 2014. That PMA approval places substantial restrictions on how Cologuard is marketed and sold, specifically, by prescription only. Additionally, the regulations governing our approval require controls on Cologuard, including, but not limited to, manufacturing facility registration, product listing with the FDA, complying with labeling requirements, maintenance of a satisfactory quality management system, and meeting post-market surveillance requirements. In addition, as a condition of our FDA approval, we are required to conduct a post-approval study. There can be no assurance that the results of this study will be satisfactory and will not cause the FDA to modify or withdraw our approval for Cologuard."
Exact knows the study will not be satisfactory! They are working day and night to improve the test, but can't get any results better than the FIT tests. The test does not work as most doctors will attest. If the test worked, they would perform about 2m tests per year. They only performed about 550k tests!
This test is a joke!